Condition: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical Neoplasms · Sponsor: Yonsei University
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma. 198 subjects will be enrolled in this study and will be assigned to three groups in a 1:1:1 ratio. 1. Group A: Dostarlimab monotherapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV 2. Group B: Dostarlimab + Bevacizumab combination therapy * First 3 cycles: Dostalimab 500mg every 3 weeks, IV * 4 cycles \~ up to 24 months: Dostalimab 1000mg every 6 weeks, IV * Bevacizumab administered IV at 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity 3. Group C: General chemotherapy (one of Pegylated liposomal doxorubicin, Doxorubicin, Paclitaxel, and Gemcitabine)
This description comes directly from the study's public registry record.
JUNGYUN LEE, Ph.D. · 82)2-2228-2237 · JUNGYUNLEE@yuhs.ac
Always discuss trial participation with your own doctor first.
| Monash Medical Centre | Clayton, Clayton Rd., Australia | Active Not Recruiting |
| Calvary Mater Newcastle | Waratah, Edith Saint, Australia | Active Not Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Grattan Saint, Australia | Active Not Recruiting |
| University of Hong Kong | Hong Kong, Pok Fu Ram, Hong Kong | Active Not Recruiting |
| Kurume University Hospital | Kurume, Fukuoka, Japan | Recruiting |
| Fukushima Medical University Hospital | Fukushima, Fukushima, Japan | Recruiting |
| Mie University Hospital | Tsu, Mie-ken, Japan | Recruiting |
| Tohoku University Hospital | Sendai, Miyagi, Japan | Recruiting |
| Niigata Cancer Center Hospital | Niigata, Niigata, Japan | Recruiting |
| Saitama Medical University International Medical Center | Hidaka, Saitama, Japan | Recruiting |
| Tokushima University Hospital | Tokushima, Tokushima, Japan | Recruiting |
| The Jikei University Hospital | Tokyo, Tokyo, Japan | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06023862